Beilu Pharmaceutical

Beijing Beilu Pharmaceutical Co., Ltd.
Short nameBeilu
Company typePublic
Traded asSZSE: 300016
IndustryPharmaceutical
Founded1992
HeadquartersBeijing
Area servedWorldwide
Beilu Pharmaceutical
Simplified Chinese北陆药业
Traditional Chinese北陸藥業
RevenueIncrease CN¥983 million (2024)
Websitebeilupharma.com

Beilu Pharmaceutical, also known as Beilu Pharma,[1] simply referred to as Beilu, is a Chinese[2] pharmaceutical company[3] founded in 1992. It went public on the Shenzhen Stock Exchange[4] in 2009 and underwritten by UBS.[5] Prior to that, it was listed on the NEEQ.[6] In 2024, the revenue of the firm reached more than 983 million yuan.[7] It is one of the key players in the global contrast media market.[8]

Headquartered in Beijing,[9] Beilu Pharma was financed by Infotech.[10] It had reached required standards to float shares on the Shenzhen second board market in May 2009.[11] In October, the company officially landed on the ChiNext[12] under the stock code "300016". The company also has an equity stake in Shihe Gene.[13] In 2022, it set up a wholly-owned subsidiary in Hong Kong.[14]

Products

Beilu Pharma mainly produces gadobutrol injections, gadopentetate dimeglumine injections, and Iohexol injections.[15] Jiuwei Zhenxin Granules and Jinlianhua Granules are the company's representative products.[7]

History

Beilu Pharma was set up in 1992.[16] In 2008, it secured more than 66.6 million yuan in funding from investors.[17] In 2009, in its GEM Board IPO, the company raised more than 300 million yuan.[18]

In May 2016, Beilu Pharma established an industry buyout fund worth 610 million yuan.[19] In 2017, its net profit amounted to more than 118 million yuan.[20] In 2020, the company raised $70.42 million.[21]

References

  1. ↑ Li Yan; Yang Ge (June 28, 2017). "Gene Bank Operator to Launch IPO Share Sale Next Week". Caixin.
  2. ↑ "Chinese Drugmakers Shine on the Global Stage". The Wall Street Journal. December 28, 2012.
  3. ↑ "Hong Kong stocks close 0.69% stronger". The Australian. June 3, 2015. Archived from the original on March 22, 2026.
  4. ↑ "Hong Kong stocks end 0.47% down, Shanghai rallies 1.69%". AFP. June 2, 2015.
  5. ↑ Chao Deng (September 12, 2012). "UBS China Looks to Smaller Firms for Growth". The Wall Street Journal.
  6. ↑ Jiazhuo G. Wang; Juan Yang (2016). Financing without Bank Loans. Springer. p. 143.
  7. 1 2 Chen Xi (April 17, 2025). "Beilu Pharmaceutical Releases Its 2024 Annual Report". Shanghai Securities Journal. Archived from the original on March 22, 2026.
  8. ↑ "Contrast Media Market 2024-2028". Research and Markets. August 19, 2024. Archived from the original on March 22, 2026.
  9. ↑ Ferguson Evans (2025). Japan and the Rise of China: Power Dynamics and Business Relations. Routledge.
  10. ↑ "Beilu Pharma Raises 66.6 Million RMB". BioSpace. August 26, 2008.
  11. ↑ Vivian Wai-yin Kwok (May 6, 2009). "The Nasdaq Of China Is Coming". Forbes.
  12. ↑ "Shenzhen Exchange Tightens ChiNext Rules". The Wall Street Journal. January 7, 2010. Archived from the original on March 22, 2026.
  13. ↑ Ma Danmeng (August 15, 2020). "Numerous genetic testing companies complete their IPOs". Caixin.
  14. ↑ "A Global and Regional Analysis: Focus on Product and Country Analysis". Research and Markets. June 12, 2023. Archived from the original on March 22, 2026.
  15. ↑ Yuxin Zhang (November 18, 2024). "Prediction of esophageal fistula in radiotherapy/chemoradiotherapy for patients with advanced esophageal cancer by a clinical-deep learning radiomics model". Springer.com. Archived from the original on March 22, 2026.
  16. ↑ "Beijing steps up investments in Tianjin and Hebei". Xinhua News Agency. Beijing Daily. February 24, 2017.
  17. ↑ Ying Huang (August 25, 2008). "Beilu Pharmaceutical Raises Funds For CT Contrast Agents". Scrip. ISSN 0143-7690. Archived from the original on March 22, 2026.
  18. ↑ Shankar Ramakrishnan; Fiona Lau; Daniel Stanton (November 19, 2009). "Equity House, Australia and New Zealand Equity House". International Financing Review. Archived from the original on March 22, 2026.
  19. ↑ Reuters Staff. "Beilu Pharmaceutical to establish industry buyout fund worth 610 mln yuan". Reuters. April 28, 2016. Archived from the original on March 22, 2026.
  20. ↑ The Competitiveness Report of Zhongguancun Listed Companies (2019). Springer. 2019. p. 286.
  21. ↑ "China Diagnostic Imaging Market Outlook to 2025". GlobalData. June 30, 2020. Archived from the original on March 22, 2026.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.